[ad_1]
AstraZeneca from the UK says late-stage trials of its Covid-19 vaccine were “highly effective” in preventing disease.
The results are based on an interim analysis of trials in the UK and Brazil of the vaccine developed by the University of Oxford and manufactured by AstraZeneca.
Siphiwe Sibeko / AP
AstraZeneca-Oxford says late-stage trials of its Covid-19 vaccine were “up to 90 percent” effective
No hospitalizations or serious cases of Covid-19 were reported in those who received the vaccine, AstraZeneca said.
“These findings show that we have an effective vaccine that will save many lives. It’s exciting that one of our dosing regimens is around 90 percent effective, ” said Professor Andrew Pollard, the trial’s lead investigator.
READ MORE:
* Covid-19: Moderna and Pfizer coronavirus vaccines look strong. This is how they compare
* Coronavirus: Second Covid-19 vaccine shows overwhelming success in US testing.
* Covid-19: Brazilian volunteer dies in Oxford coronavirus vaccine trial
* The second trial of the Covid-19 vaccine was stopped due to an unexplained illness
The trial looked at two different dosing regimens: a half dose of the vaccine followed by a full dose with an interval of at least one month was 90 percent effective. A second regimen using two full doses one month apart was 62% effective. The combined results showed an average efficacy rate of 70 percent.
“The efficacy and safety of this vaccine confirm that it will be very effective against Covid-19 and will have an immediate impact on this public health emergency,” said AstraZeneca CEO Pascal Soriot.
“Additionally, the vaccine’s simple supply chain and our non-profit promise and commitment to broad, equitable and timely access means it will be affordable and available globally, supplying hundreds of millions of doses with approval.
Two other drug makers, Pfizer and Moderna, reported preliminary results from late-stage trials last week showing their Covid-19 vaccines were nearly 95% effective.
